GlassScriptPhysician profile
Laura Thomson
NPI 1710358650
$24,646.80
in general payments reported to CMS, 2019-2025
27 companies · $890 in 2025
The $890 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,181 · 2022: $1,428 · 2023: $17K · 2024: $4,051 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $3,789 · Travel and Lodging: $586 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,375.00 |
| Food and Beverage | $3,788.71 |
| Travel and Lodging | $585.57 |
| Education | $288.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,969.60 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,030.54 | 2021-2024 | Caplyta |
| Alkermes, INC. | $756.32 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $660.30 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $519.97 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $461.63 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $221.41 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $207.91 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $196.99 | 2021-2024 | Rexulti |
| Abbott Laboratories | $154.35 | 2022 | |
| Sunovion Pharmaceuticals INC. | $63.83 | 2021 | |
| Glaxosmithkline, LLC. | $60.51 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.21 | 2024-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $48.60 | 2025 | Hetlioz, Fanapt |
| Avanir Pharmaceuticals, INC. | $30.87 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $29.59 | 2024 | Ingrezza |
| Depuy Synthes Sales INC. | $22.28 | 2023 | Na |
| Aroa Biosurgery Incorporated | $21.13 | 2022 | |
| Ethicon US, LLC | $20.09 | 2022 | |
| Hologic Sales and Service, LLC | $18.28 | 2023 | Novasure |
| Merck Sharp & Dohme LLC | $15.91 | 2023 | Rotateq, Vaxneuvance, Gardasil 9 |
| Almatica Pharma LLC | $15.60 | 2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $15.50 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.02 | 2025 | Cobenfy |
| Integra Lifesciences Corporation | $14.29 | 2022 | |
| Amgen INC. | $12.95 | 2022 | |
| Eisai INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Thomson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.